Cargando…
Among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477662/ https://www.ncbi.nlm.nih.gov/pubmed/37675330 http://dx.doi.org/10.21037/atm-23-903 |
| _version_ | 1785101182202544128 |
|---|---|
| author | Babaier, Abdulaziz Ghatage, Prafull |
| author_facet | Babaier, Abdulaziz Ghatage, Prafull |
| author_sort | Babaier, Abdulaziz |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10477662 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104776622023-09-06 Among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most? Babaier, Abdulaziz Ghatage, Prafull Ann Transl Med Editorial Commentary AME Publishing Company 2023-03-28 2023-08-30 /pmc/articles/PMC10477662/ /pubmed/37675330 http://dx.doi.org/10.21037/atm-23-903 Text en 2023 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Babaier, Abdulaziz Ghatage, Prafull Among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most? |
| title | Among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most? |
| title_full | Among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most? |
| title_fullStr | Among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most? |
| title_full_unstemmed | Among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most? |
| title_short | Among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most? |
| title_sort | among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most? |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477662/ https://www.ncbi.nlm.nih.gov/pubmed/37675330 http://dx.doi.org/10.21037/atm-23-903 |
| work_keys_str_mv | AT babaierabdulaziz amongpatientswithadvancedovariancarcinomawhobenefitsfrombevacizumabthemost AT ghatageprafull amongpatientswithadvancedovariancarcinomawhobenefitsfrombevacizumabthemost |